Table 4 Summary of the survival rate for patients with early-stage ASC in recent years
Study | Cell type | FIGO | 5-y OS | 5-y DFS |
|---|---|---|---|---|
Yasuda et al. [2] | ASC (n = 28) AC (n = 81) | IB1 | 82.4% 92.4% | 82% 92% |
Barquet et al. [19] | ASC (n = 14) AC (n = 57) | IA2-IIA1 | 100% 97.8% | 92.3% 98.1% |
Mabuchi et al. [11] | ASC (n = 20) AC (n = 143) | IA2-IIB | – | 79.2% 74.1% |
Beak et al. [20] | ASC (n = 72) AC (n = 265) | IA2-II | 88% 92% | 85% 88% |
Twu et al. [21] | ASC (n = 321) AC (n = 811) | I-II | 94.2% (low risk) 65.8% (high risk) | 88.6% (low risk) 55.1% (high risk) |
Current study | ASC (n = 131) | IB1-IIA2 | 71.4% | 51% |